Quick Answer
Connect Biopharma Holdings Ltd reported Operating Income of -$58.07 million for fiscal year 2025.
Connect Biopharma Holdings Ltd Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$58.07M | -158.7% |
| 2024 | -$22.45M | +67.5% |
| 2023 | -$69.06M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$17.68M | -27.7% | -31.7% |
| June 30, 2025 | -$13.42M | -198.4% | -17.3% |
| March 31, 2025 | -$11.45M | +9.4% | +17.3% |
| September 30, 2024 | -$13.85M | — | -201.5% |
| June 30, 2024 | $13.65M | — | +208.0% |
| March 31, 2024 | -$12.63M | — | — |
- Connect Biopharma Holdings Ltd showed a decrease of -158.7% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Connect Biopharma Holdings Ltd’s operating income has grown by 15.9% (from -$69.06 million to -$58.07 million).
- The most recent figure is from Connect Biopharma Holdings Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: